(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally...
Stats | |
---|---|
Dagens volum | 200.00 |
Gjennomsnittsvolum | 13.00 |
Markedsverdi | 0.00 |
Last Dividend | $0.411 ( 2022-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Vifor Pharma AG Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Vifor Pharma AG Økonomi
Annual | 2021 |
Omsetning: | $1.82B |
Bruttogevinst: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2021 |
Omsetning: | $1.82B |
Bruttogevinst: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2020 |
Omsetning: | $1.71B |
Bruttogevinst: | $1.00B (58.89 %) |
EPS: | $1.108 |
FY | 2019 |
Omsetning: | $1.88B |
Bruttogevinst: | $1.12B (59.44 %) |
EPS: | $0.490 |
Financial Reports:
No articles found.
Vifor Pharma AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.371 | 2016-05-02 |
Last Dividend | $0.411 | 2022-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $2.44 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.49 | |
Div. Directional Score | 6.34 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
CHBH | Ex Dividend Knight | 2023-10-12 | Quarterly | 0 | 0.00% | |
SMFKY | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
GELYY | Ex Dividend Knight | 2023-06-02 | Annually | 0 | 0.00% | |
ADRNY | Ex Dividend Knight | 2023-08-11 | Annually | 0 | 0.00% | |
NCMGY | Ex Dividend Knight | 2023-08-22 | Annually | 0 | 0.00% | |
CNPWM | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
TGOPY | Ex Dividend Knight | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
HNHPF | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
ARZGY | Ex Dividend Junior | 2023-05-22 | Annually | 0 | 0.00% | |
PEBC | Ex Dividend Knight | 2023-09-08 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.09 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0520 | 1.200 | 8.27 | 9.92 | [0 - 0.3] |
returnOnEquityTTM | 0.0752 | 1.500 | -0.276 | -0.414 | [0.1 - 1] |
payoutRatioTTM | 0.715 | -1.000 | 2.85 | -2.85 | [0 - 1] |
currentRatioTTM | 1.914 | 0.800 | 5.43 | 4.34 | [1 - 3] |
quickRatioTTM | 1.013 | 0.800 | 8.75 | 7.00 | [0.8 - 2.5] |
cashRatioTTM | 1.013 | 1.500 | 5.49 | 8.23 | [0.2 - 2] |
debtRatioTTM | 0.115 | -1.500 | 8.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 22.19 | 1.000 | 2.89 | 2.89 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.53 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.168 | -1.500 | 9.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.632 | 1.000 | 2.80 | 2.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.109 | 1.000 | 9.81 | 9.81 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.898 | 1.000 | 6.12 | 6.12 | [0.2 - 2] |
assetTurnoverTTM | 0.358 | 0.800 | -0.948 | -0.758 | [0.5 - 2] |
Total Score | 10.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 42.54 | 1.000 | 5.80 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0752 | 2.50 | -0.177 | -0.414 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.68 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.715 | 1.500 | 2.85 | -2.85 | [0 - 1] |
pegRatioTTM | -2.43 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.289 | 1.000 | 5.27 | 0 | [0.1 - 0.5] |
Total Score | 2.49 |
Vifor Pharma AG
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.